{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"210"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"description":"MTD is defined as the dose level at which no more than 1 of 6 subjects experience a dose-limiting toxicity (DLT) during one cycle of treatment. A DLT is defined using the Common Terminology Criteria in Adverse Events (CTCAE) v4.0 and is related or possibly drug related, such as neutropenia Grade 4 for \\>7 days duration, febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infection), or Grade 3 thrombocytopenia. Death due to drug related adverse events.","groups":[{"description":"All participants in phase I DL1-DL4.","id":"OG000","title":"All Participants"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"End of Cycle 1, approximately 3 weeks","title":"Ph I: Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of VX-970 (M6620)","type":"PRIMARY","unitOfMeasure":"mg/m^2"}